Measurement of apolipoprotein E (apoE) in cerebrospinal fluid

Neurochemical Research

Volumn 25, Issue 4, 2000, Pages 511-517

  Hesse, Camilla ^a,c   Larsson, Helena ^a   Fredman, Pam ^a   Minthon, Leimart ^d   Andreasen, Niels ^b   Davidsson, Pia ^a   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Pitea River Valley Hospital   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d NONE

Author keywords

Alzheimer's disease; Apolipoprotein E; Cerebrospinal fluid; ELISA; Neurodegeneration

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN INJURY; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NERVE REGENERATION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

AGED; ALLELES; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANTIBODY SPECIFICITY; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; POLYSORBATES; POLYSTYRENES; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TEMPERATURE;

EID: 0034029839     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007516210548     Document Type: Article

References (28)

1. Mahley, R. W. 1988. Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology. Science. 240:622-30.
2. Boyles, J. K., Pitas, R. E., Wilson, E., Mahley, R. W., and Taylor, J. M. 1985. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76:1501-13.
3. Swanson, L. W., Simmons, D. M., Hofmann, S. L., Goldstein, J. L., and Brown, M. S. 1988. Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc. Natl. Acad. Sci. USA. 85:9821-5.
4. Poirier, J. 1994. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. TINS. 17:525-30.
5. Handelmann, G. E., Boyles, J. K., Weisgraber, K. H., Mahley, R. W., and Pitas, R. E. 1992. Effects of apolipoprotein E, β-very low density lipoproteins, and cholesterol on extension of neurites by rabbit dorsal ganglion neurons in vitro. J. Lipid. Res. 33:1677-88.
6. Roheim, P. S., Carey, M., Forte, T., and Vega, G. L. 1979. Apolipoproteins in human cerebrospinal fluid. Proc. Natl. Acad. Sci. USA, 76:4646-9.
7. Roses, A. D. 1996. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47:387-400.
8. Blennow, K., Hesse, C., and Fredman, P. 1994. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport. 5:2534-2536.
9. Landén, M., Hesse, C., Fredman, P., Regland, B., Wallin, A., and Blennow, K. 1996. Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoe4 isoform. Dementia. 7:273-8.
10. Pirttilä, T., Mehta, P. D., Lehtimaki, T., Kim, K. S., Sersen, E. A., Frey, H., Nikkari, T., and Wisniewski, H. M. 1994. Relationship between apolipoprotein E4 allele and CSF amyloid β-protein in Alzheimer's disease and controls. Neurosci. Res. Commun. 15:201-7.
11. Lefranc, D., Vermersch, P., Dallongeville, J., Daems-Monpeurt, C., Petit, H., and Delacourte, A. 1996. Relevance of the quantifcation of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease
12. Hahne, S., Nordstedt, C., Åhlin, A., and Nybäck, H. 1997. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healty controls. Neurosci. Lett. 224:99-102.
13. Merched, A., Blain, H., Visvikis, S., Herbeth, B., Jeandel, C., and Siest, G. 1997. Cerebrospinal fluid apolipoprotein e level is increased in late-onset Alzheimer's disease. J. Neuro. Sci. 145:33-9.
14. Lindh, M., Blomberg, M., Jensen, M., Basun, H., Lannfelt, L., Engvall, B., Scharnagel, H., März, W., Wahlund, L. O., and Cowburn, R. 1997. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci. Lett. 229:85-8.
15. Blennow, K., Fredman, P., Wallin, A., Gotffries, C. G., Svennerholm, L. 1993. Protein analyses in cerebrospinal fluid: I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur. Neurol. 33:126-8.
16. Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M., Wallin, A., Andreasen, N., Seubert, P., Van De Voorde, A., Vanmechelen, E. 1998. Development of a specific diagnostic test for measurements of β-amyloid (1-42) [βA4(1-42)] in CSF. Pages 773-8, in Fisher, A., Hanin, I., Yoshida, M. (eds.), Progress in Alzheimer's and Parkinson's diseases, Plenum Press, New York.
17. Folstein, M., Folstein, S., and McHugh, P. 1975. "Mini-Mental State" A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:189-98.
18. Laemmli, U. K. 1972. Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature. 227:680-5.
19. Leary, J. J., Brigati, D. J., and Ward, D. C. 1983. Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA and RNA immobilized in nitrocellulose Bio. Blots. Proc. Natl. Acad. Sci. USA. 80:4045-9.
20. Høgåsen, K., Mollnes, T. E., Tschopp, J., and Harboe, M. 1992. Quantitation of vitronectin and clusterin. Pitfalls and solutions in enzyme immunoassays for adhesive proteins. J. Immuno. Meth. 160:107-15.
21. Bellosta, S., Nathan. B., Orth, M., Dong, L. M., Mahley, R., and Pitas, R. 1995. Stable expression and secretion of apolipoprotein E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 270:27063-71.
22. Taddei, K., Clarnette, R., Gandy, S., and Martins, R. 1997. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci. Lett. 223:29-32.
23. Pirttilä, T., Koivisto, K., Metha, P., Reinikainen, K., Kim, K., Kikku, O., Heinonen, E., Soininen, H., Riekkinen, P., and Wisniewski, H. 1998. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci. Lett. 249:21-4.
24. Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M, Salvesen, G. S., PericakVance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., and Roses, A. D. 1993. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. 90:8098-102.
25. LaDu, M., Falduto, M., Manelli, A., Reardon, C., Getz, G., and Frail, D. 1994. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269:23403-6.
26. Wisniewski, T., Golabek, A., Matsubara, E., Ghiso, J., and Frangione, B. 1993. Apolipoprotein E: binding to soluble Alzheimer's β-amyloid. Biochem. Biophys. Res. Comm. 192:359-65.
27. Carlsson, J., Armstrong, V. W., Reiber, H., Felgenhauer, K., and Seidel, D. 1991. Clinical relevance of quantification of apolipoprotein E in cerebrospinal fluid. Clin. Chim. Acta. 196:167-176.
28. Song, H., Saito, K., Seishima, M., Noma, A., Urakami, K., and Nakashima, K. 1997. Cerebrospinal fluid apoE and apoA-I concentrations in early- and late-onset Alzheimer's disease. 231:175-8.